379 related articles for article (PubMed ID: 28006858)
21. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
22. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
[TBL] [Abstract][Full Text] [Related]
23. HIV-positive gay men's knowledge and perceptions of Human Papillomavirus (HPV) and HPV vaccination: A qualitative study.
Grace D; Gaspar M; Paquette R; Rosenes R; Burchell AN; Grennan T; Salit IE
PLoS One; 2018; 13(11):e0207953. PubMed ID: 30496221
[TBL] [Abstract][Full Text] [Related]
24. Prevention of Human Papillomavirus Infection. Beyond Cervical Cancer: A Brief Review.
Medeiros R; Vaz S; Rebelo T; Figueiredo-Dias M
Acta Med Port; 2020 Mar; 33(3):198-201. PubMed ID: 32130098
[TBL] [Abstract][Full Text] [Related]
25. Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none.
El-Zein M; Richardson L; Franco EL
J Clin Virol; 2016 Mar; 76 Suppl 1(Suppl 1):S62-S68. PubMed ID: 26631958
[TBL] [Abstract][Full Text] [Related]
26. Novel Approaches for Vaccination Against HPV-Induced Cancers.
King E; Ottensmeier C; Pollock KGJ
Curr Top Microbiol Immunol; 2017; 405():33-53. PubMed ID: 25735921
[TBL] [Abstract][Full Text] [Related]
27. Eurogin 2010 roadmap on cervical cancer prevention.
Franceschi S; Denny L; Irwin KL; Jeronimo J; Lopalco PL; Monsonego J; Peto J; Ronco G; Sasieni P; Wheeler CM
Int J Cancer; 2011 Jun; 128(12):2765-74. PubMed ID: 21207409
[TBL] [Abstract][Full Text] [Related]
28. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
29. Carcinogenic human papillomavirus infection.
Schiffman M; Doorbar J; Wentzensen N; de Sanjosé S; Fakhry C; Monk BJ; Stanley MA; Franceschi S
Nat Rev Dis Primers; 2016 Dec; 2():16086. PubMed ID: 27905473
[TBL] [Abstract][Full Text] [Related]
30. Impact of HPV vaccination: health gains in the Italian female population.
Marcellusi A
Popul Health Metr; 2017 Sep; 15(1):36. PubMed ID: 28962572
[TBL] [Abstract][Full Text] [Related]
31. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.
Drolet M; Bénard É; Boily MC; Ali H; Baandrup L; Bauer H; Beddows S; Brisson J; Brotherton JM; Cummings T; Donovan B; Fairley CK; Flagg EW; Johnson AM; Kahn JA; Kavanagh K; Kjaer SK; Kliewer EV; Lemieux-Mellouki P; Markowitz L; Mboup A; Mesher D; Niccolai L; Oliphant J; Pollock KG; Soldan K; Sonnenberg P; Tabrizi SN; Tanton C; Brisson M
Lancet Infect Dis; 2015 May; 15(5):565-80. PubMed ID: 25744474
[TBL] [Abstract][Full Text] [Related]
32. The Human Papillomavirus as a Common Pathogen in Oropharyngeal, Anal and Cervical Cancers.
Otter S; Whitaker S; Chatterjee J; Stewart A
Clin Oncol (R Coll Radiol); 2019 Feb; 31(2):81-90. PubMed ID: 30385006
[TBL] [Abstract][Full Text] [Related]
33. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review.
Harder T; Wichmann O; Klug SJ; van der Sande MAB; Wiese-Posselt M
BMC Med; 2018 Jul; 16(1):110. PubMed ID: 30016957
[TBL] [Abstract][Full Text] [Related]
34. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
35. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
36. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
Adams M; Jasani B; Fiander A
Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
[TBL] [Abstract][Full Text] [Related]
37. Infection of human papillomaviruses in cancers of different human organ sites.
Shukla S; Bharti AC; Mahata S; Hussain S; Kumar R; Hedau S; Das BC
Indian J Med Res; 2009 Sep; 130(3):222-33. PubMed ID: 19901431
[TBL] [Abstract][Full Text] [Related]
38. [HPV: Carcinogenic implications and preventive measures].
Bernichon E; Espenel S; Méry B; Trone JC; Rehalia-Blanchard A; He YM; Rancoule C; Magné N
Presse Med; 2019; 48(7-8 Pt 1):756-766. PubMed ID: 31307878
[TBL] [Abstract][Full Text] [Related]
39. Human Pappilomavirus (HPV) induced cancers and prevention by immunization.
Khaliq SA; Shyum Naqvi SB; Fatima A
Pak J Pharm Sci; 2012 Oct; 25(4):763-72. PubMed ID: 23009992
[TBL] [Abstract][Full Text] [Related]
40. High-risk human papillomavirus genotypes in cervical lesions and vaccination challenges in China.
Xu QX; Zhang ZY
Asian Pac J Cancer Prev; 2015; 16(6):2193-7. PubMed ID: 25824736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
